{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:21:21Z","timestamp":1787556081744,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cmi.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:09:21Z","timestamp":1777129761000},"page":"1384-1387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic prophylaxis: a sharp tool that could be blunted easily"],"prefix":"10.1016","volume":"32","author":[{"given":"Marek","family":"Stefan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Krutova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.04.018_bib1","series-title":"The antibiotic era: Reform, resistance, and the pursuit of a rational therapeutics","author":"Podolsky","year":"2015"},{"key":"10.1016\/j.cmi.2026.04.018_bib2","first-page":"24","article-title":"Diagnosis and management of community-acquired pneumonia: An official American Thoracic Society clinical practice guideline","volume":"212","author":"Jones","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.04.018_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/cid\/ciaf625","article-title":"Infectious Diseases Society of America (IDSA) position statement: Why IDSA did not endorse the community-acquired pneumonia guidelines 2025 update","volume":"82","author":"Klompas","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.018_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20563","article-title":"Overprescription of antibiotics for treating hospitalized COVID-19 patients: A systematic review & meta-analysis","volume":"9","author":"Rabbi","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.cmi.2026.04.018_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/irv.12398","article-title":"The frequency of influenza and bacterial coinfection: A systematic review and meta-analysis","volume":"10","author":"Klein","year":"2016","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.cmi.2026.04.018_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/ciaf687","article-title":"Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays","volume":"82","author":"Biebelberg","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.018_bib7","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1093\/cid\/ciaa1239","article-title":"Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): A multi-hospital cohort study","volume":"72","author":"Vaughn","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.018_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"Postexposure doxycycline to prevent bacterial sexually transmitted infections","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.04.018_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7302a1","article-title":"CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024","volume":"73","author":"Bachmann","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2026.04.018_bib10","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/jac\/dkaf366","article-title":"Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study","volume":"80","author":"Palacios","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.04.018_bib11","doi-asserted-by":"crossref","first-page":"9206","DOI":"10.1038\/s41467-025-64261-w","article-title":"Bacterial sexually transmitted infections and related antibiotic use among individuals eligible for doxycycline post-exposure prophylaxis in the United States","volume":"16","author":"Parker","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2026.04.018_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaf120","article-title":"Tetracycline-resistant Neisseria gonorrhoeae global estimates-impacts on doxycycline post-exposure prophylaxis implementation and monitoring: a systematic review","volume":"7","author":"Do","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.04.018_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-024-03274-2","article-title":"Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome","volume":"31","author":"Chu","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2026.04.018_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40121-025-01270-8","article-title":"A review of doxycycline post-exposure prophylaxis and its implications for antimicrobial resistance and the human microbiome","volume":"15","author":"Fernandez-Ibanez","year":"2026","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2026.04.018_bib15","series-title":"The selection and use of essential medicines, 2025: WHO AWaRe (Access, Watch, Reserve) classification of antibiotics for evaluation and monitoring of use","year":"2025"},{"key":"10.1016\/j.cmi.2026.04.018_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.53168","article-title":"Risk of household secondary invasive Group A streptococcal infections after a prophylaxis policy change","volume":"9","author":"de Gier","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2026.04.018_bib17","article-title":"Adaptation of the WHO AWaRe (Access, Watch, Reserve) antibiotic classification to support national antimicrobial stewardship priorities in the UK: findings from a modified Delphi approach to achieve expert consensus","volume":"7","author":"Bou-Antoun","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2026.04.018_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106468","article-title":"Antibiotic chemoprophylaxis for close contacts of invasive group A streptococcus in community settings: Evidence review","volume":"90","author":"Watts","year":"2025","journal-title":"J Infect"},{"issue":"Suppl 2","key":"10.1016\/j.cmi.2026.04.018_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.04.018_bib20","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.cmi.2025.08.004","article-title":"Screening and targeted prophylaxis for Clostridioides difficile infection","volume":"31","author":"Ziegler","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.04.018_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2024.105349","article-title":"Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: A retrospective cohort study","volume":"26","author":"Najjar-Debbiny","year":"2024","journal-title":"Microbes Infect"},{"key":"10.1016\/j.cmi.2026.04.018_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/tid.70025","article-title":"Prophylactic vancomycin in the primary prevention of Clostridium difficile in allogeneic stem cell transplant","volume":"27","author":"Fusco","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2026.04.018_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17834","article-title":"Oral vancomycin for prevention of recurrent Clostridioides difficile infection: A randomized clinical trial","volume":"8","author":"Keating","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2026.04.018_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cid\/ciae087","article-title":"Reduced vancomycin susceptibility in Clostridioides difficile is associated with lower rates of initial cure and sustained clinical response","volume":"79","author":"Eubank","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:50:27Z","timestamp":1787554227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1198743X26002065"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.04.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic prophylaxis: a sharp tool that could be blunted easily","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}